Alex Hennessey, MD
Urology · Danbury, CTNPI 1811350424
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,607 of the $5,872 with a category attached, or 78.5%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,728, 6.4 times the $423 reported in 2021.
Across 164 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Histosonics, Inc.$1K
- Teleflex LLC$1K
- Sumitomo Pharma America, Inc.$387
- Merck$331
- Medtronic$279
- Progenics Pharmaceuticals, Inc.$224
- plus $2K from 34 others
What the payments were for
- Travel & lodging$1,16520%
- Food & beverage$4,60778%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Histosonics, Inc. | 2 | $1,164 |
| Teleflex LLC | 28 | $1,046 |
| Sumitomo Pharma America, Inc. | 16 | $387 |
| Merck | 10 | $331 |
| Medtronic | 6 | $279 |
| Progenics Pharmaceuticals, Inc. | 6 | $224 |
| Endo USA, Inc. | 10 | $207 |
| Myovant Sciences Inc. | 8 | $185 |
| Boston Scientific | 3 | $174 |
| Astellas Pharma US Inc | 4 | $164 |
| Novartis | 5 | $150 |
| AbbVie | 6 | $150 |
| EDAP Technomed Inc | 2 | $136 |
| Endo Pharmaceuticals Inc. | 6 | $126 |
| Pfizer | 5 | $123 |
| Tolmar, Inc. | 5 | $118 |
| Telix Pharmaceuticals | 2 | $78 |
| Coloplast | 4 | $77 |
| Urogen Pharma, Inc. | 3 | $73 |
| Agiliti Surgical, Inc. | 1 | $60 |
| Bayer | 2 | $55 |
| Mission Pharmacal Company | 3 | $50 |
| 180 Medical, Inc. | 2 | $39 |
| KARL Storz Endoscopy-america | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| Tolmar Pharmaceuticals, Inc. | 2 | $35 |
| Olympus America Inc. | 2 | $35 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Vertex | 1 | $32 |
| Amgen | 2 | $32 |
| Axonics, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Civco Medical Instruments | 1 | $28 |
| Calyxo, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $25 |
| Urovant Sciences Inc | 2 | $24 |
| BD | 1 | $22 |
| Immunitybio, Inc. | 1 | $21 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$364
- UroLift$129
- KEYTRUDA$125
- PYLARIFY$115
- Axonics$112
- PERCEPT PC BRAINSENSE$111
How this compares
$5,872 in reported general payments places this provider in the 75th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 88 | $58,352 |
| GemtesaVibegron | 45 | $38,274 |
| OrgovyxRelugolix | 11 | $30,088 |
| Tamsulosin Hcl | 633 | $8,091 |
| Finasteride | 261 | $3,945 |
| Testosterone | 16 | $2,283 |
| Estradiol | 26 | $1,908 |
| Silodosin | 25 | $1,676 |
| Dutasteride | 36 | $1,201 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 51 | $1,004 |
| Trospium Chloride | 11 | $772 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 66 | $344 |
| Oxybutynin Chloride | 51 | $255 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $240 |
| Cephalexin | 36 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $387 | $68,36256 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $58,35288 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 urology providers in Connecticut.
Other urology in Danbury
- Michael GoltzmanDanbury$10K
- John BrunoDanbury$9K
- Stanford BroderDanbury$8K
- Jeffrey GorelickDanbury$5K
- Edward BeckDanbury$5K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.